Federal Circuit Upholds Jury Award, Weighs in on Willfulness Standard, in Adynovate® Dispute
Patterson Belknap Webb & Tyler | Biologics Blog
by
3y ago
According to the Federal Circuit, $173 million was the right damages award for almost three years of patent infringement resulting from Baxalta’s sale of its biologic product Adynovate® (Antihemophilic Factor (Recombinant), PEGylated).  In Bayer Healthcare LLC v. Baxalta Inc., et al., Nos. 2019-2418, 2020-1017 (Fed. Cir. 2021), the circuit court upheld an award to Bayer ..read more
Visit website
Sandoz Petitions the Supreme Court for Review of Enbrel® Patent License
Patterson Belknap Webb & Tyler | Biologics Blog
by
3y ago
The fight over proposed Enbrel® (etanercept) biosimilar Erelzi® continues. Sandoz Inc., Sandoz International GmbH and Sandoz GmbH (“Sandoz”) recently filed a petition for certiorari requesting review of the judgement of the Federal Circuit on whether: [a] patent owner [may] avoid the rule against double patenting by buying all of the substantial rights to a second ..read more
Visit website
Federal Circuit Axes Amgen Antibody Patents, Finding Lack of Enablement
Patterson Belknap Webb & Tyler | Biologics Blog
by
3y ago
The Federal Circuit considered its 35 U.S.C. § 112 enablement case law and found that “the enablement inquiry for claims that include functional requirements”—in this case, claims to antibodies defined by their function—“can be particularly focused on the breadth of those requirements, especially where predictability and guidance fall short.”  Dkt. 132 at 10.  In Amgen ..read more
Visit website
FDA Approves Breyanzi®—A New Biologic for Treating Large B-Cell Lymphoma
Patterson Belknap Webb & Tyler | Biologics Blog
by
3y ago
On February 5, 2021, the FDA approved Juno Therapeutics, Inc.’s Breyanzi® (lisocabtagene maraleucel) for “treatment of adult patients with relapsed or refractory large B-cell lymphoma.”  Juno, a Bristol-Myers Squibb Company, was authorized to manufacture Breyanzi at its Bothell, Washington facility and provide it to patients under a risk evaluation and mitigation strategy (REMS).  Breyanzi was designated ..read more
Visit website
2021 Biosimilar Approval and Litigation Update
Patterson Belknap Webb & Tyler | Biologics Blog
by
3y ago
The last two years saw the launch of several biosimilars.  Looking ahead to 2021, several others may be on the horizon.  In 2019-2020, the FDA approved thirteen biosimilars directed to seven reference products.  Eight of the approved biosimilars have launched, while five are either embroiled in litigation or awaiting agreed-upon launch dates.  Over the last ..read more
Visit website
Rehearing Denied in Federal Circuit Hatch-Waxman Venue Case
Patterson Belknap Webb & Tyler | Biologics Blog
by
3y ago
The Federal Circuit has spoken.  In a per curiam opinion, it denied Valeant’s petition for rehearing by the panel and rehearing en banc.  A case watched closely by the biotechnology and pharmaceutical industries, the Federal Circuit held in Valeant Pharms. N. Am. LLC v. Mylan Pharms. Inc. that venue in Hatch-Waxman cases brought under 35 U.S.C ..read more
Visit website
Opposition to Rehearing Filed in Major Federal Circuit Case Narrowing Hatch-Waxman Venue
Patterson Belknap Webb & Tyler | Biologics Blog
by
3y ago
Last week, Mylan filed a brief in opposition to Valeant’s petition for rehearing en banc in Valeant Pharms. N. Am. LLC v. Mylan Pharms. Inc., No. 2019-2402. In November, a Federal Circuit panel held that venue in Hatch-Waxman cases brought under 35 U.S.C. § 271(e)(2)(A) is proper “only in districts where actions related to the submission of ..read more
Visit website
WTO to Discuss Member Proposal to Waive IP Rights for COVID-19 Technologies
Patterson Belknap Webb & Tyler | Biologics Blog
by
3y ago
On October 2, 2020, India and South Africa urged the World Trade Organization (WTO) Trade-Related Aspects of Intellectual Property Rights (TRIPS) Council to temporarily waive the obligation of member states under the TRIPS Agreement to protect intellectual property rights for technologies related to the “prevention, containment or treatment” of COVID-19. Kenya, Eswatini, Pakistan, Mozambique, and Bolivia ..read more
Visit website
Rehearing Requested in Major Federal Circuit Case Narrowing Venue in Hatch-Waxman Cases
Patterson Belknap Webb & Tyler | Biologics Blog
by
3y ago
Earlier this month, Valeant Pharmaceuticals North America LLC (“Valeant”) filed a petition for rehearing en banc in Valeant Pharms. N. Am. LLC v. Mylan Pharms. Inc., No. 2019-2402, arguing that the Federal Circuit panel’s decision limiting venue in Hatch-Waxman cases conflicts with precedent regarding “what the act of infringement is” and “where the act of infringement ..read more
Visit website
FDA’s Draft Guidance for Industry Seeks to Answer Questions on Biosimilar Interchangeability
Patterson Belknap Webb & Tyler | Biologics Blog
by
3y ago
FDA has published new draft guidance for industry titled “Biosimilarity and Interchangeability: Additional Draft Q&As on Biosimilar Development and the BPCI Act.”  The draft guidance supplements two prior documents concerning biosimilar interchangeability published in December 2018.[1]  This new guidance, in particular, has some useful information for prospective applicants who seek licensure of an “interchangeable” biosimilar ..read more
Visit website

Follow Patterson Belknap Webb & Tyler | Biologics Blog on FeedSpot

Continue with Google
Continue with Apple
OR